The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Open accessAbstract
Background Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1.Methods ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423.Findings Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]). Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3. The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]). Immune-mediated events were manageable with standard treatment guidelines.Interpretation In patients with advanced and heavily pretreated NSCLC, the clinical activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents. Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.Funding AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to EGFR-mutation, ALK rearrangement is also related to the poor response to α-PD-1/PD-L1 [199].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,782
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationRizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Self-citation
Cited by
Sorted by citations
Items 101–200 of 570
Ye, J., Ji, X., Dennis, P. A., Abdullah, H. A., & Mukhopadhyay, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1956 · Cited by 69
Self-citationZhao, J., Xu, W., Zhou, F., Zhang, X., Zhou, M., Miao, D., Yu, L., Zhang, Y., Fan, J., Zhou, C., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01085-z · Cited by 68
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Qiu, Z., Chen, Z., Zhang, C., & Zhong, W. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0143-z · Cited by 64
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 65
Balaji, A., Zhang, J., Wills, B., Marrone, K. A., Elmariah, H., Yarchoan, M. M., Zimmerman, J. W., Hajjir, K., Venkatraman, D., Armstrong, D. K., et al. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00703 · Cited by 62
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
Cremolini, C., Vitale, E., Rastaldo, R., & Giachino, C. (2021) · Nanomaterials · doi:10.3390/nano11030661 · Cited by 64
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 61
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60
Chen, D., Wang, R., Chen, Y., Cao, F., Zhang, X., Yan, F., Chen, L., Zhu, H., Yu, Z., & Feng, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.046 · Cited by 59
Self-citationDurvalumab in cancer medicine: a comprehensive review
Argote, J. A., & Dasanu, C. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1635115 · Cited by 62
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Self-citationNie, R., Chen, F., Yuan, S., Luo, Y.-S., Chen, S., Chen, Y., Chen, X., Chen, Y.-B., Li, Y., & Zhou, Z. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.011 · Cited by 59
Self-citationDeschênes‐Simard, X., Richard, C., Galland, L., Blais, F., Desîlets, A., Malo, J., Cvetkovic, L., Belkaïd, W., Elkrief, A., Gagné, A., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.018 · Cited by 57
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Al-Showbaki, L., Wilson, B. E., Tamimi, F., Moltó, C., Mittal, A., Cescon, D. W., & Amir, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005854 · Cited by 56
Wei, F., Azuma, K., Nakahara, Y., Saito, H., Matsuo, N., Tagami, T., Kouro, T., Igarashi, Y., Tokito, T., Kato, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006788 · Cited by 58
Self-citationChimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
Boothman, A.-M., Scott, M. L. J., Ratcliffe, M., Whiteley, J. L., Dennis, P. A., Wadsworth, C., Sharpe, A. D., Rizvi, N. A., Garassino, M. C., & Walker, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.025 · Cited by 56
Self-citationBerghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 56
Self-citationLiu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113618 · Cited by 57
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
Sridhar, S., Paz-Ares, L. G., Liu, H., Shen, K., Morehouse, C., Rizvi, N. A., Segal, N. H., Jin, X., Zheng, Y., Narwal, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.020 · Cited by 53
Self-citationPu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Garassino, M. C., Cho, B. C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Léna, H., Jaime, J. C., Gray, J. E., Powderly, J. D., CHOUAID, C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.032 · Cited by 53
Self-citationPrognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
Niu, Y., Lin, A., Luo, P., Zhu, W., Wei, T., Tang, R., Guo, L., & Zhang, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01213 · Cited by 54
Molina, G. E., Zubiri, L., Cohen, J. V., Durbin, S., Petrillo, L. A., Allen, I. M., Murciano‐Goroff, Y. R., Dougan, M. L., Thomas, M. F., Faje, A. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13740 · Cited by 54
Self-citationTripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
Jin, R., Liu, C., Zheng, S., Wang, X., Feng, X., Li, H., Sun, N., & He, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0121 · Cited by 55
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
Liu, S., Yu, J. S., Zhang, H., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860563 · Cited by 53
Current concepts of non-coding RNA regulation of immune checkpoints in cancer
Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 51
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
Shields, M. D., Chen, K., Dutcher, G., Patel, I., & Pellini, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169006 · Cited by 51
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Lau, D., Garçon, F., Chandra, A., Lechermann, L. M., Aloj, L., Chilvers, E. R., Corrie, P. G., Okkenhaug, K., & Gallagher, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01514 · Cited by 51
Rong, Q., Wang, F., Guo, Z., Hu, Y., An, S., Luo, M., Zhang, H., Wu, S., Huang, H., & Fu, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01374-y · Cited by 49
Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
Zhou, L., Zhang, M., Li, R., Xue, J., & Lü, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03360-1 · Cited by 47
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 46
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
Yang, H. J., Shen, K., Zhu, C., Li, Q., Zhao, Y., & Ma, X. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s162214 · Cited by 45
Mei, T., Wang, T., & Zhou, Q. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01324-0 · Cited by 47
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
Bhatlapenumarthi, V., Patwari, A., & Harb, A. J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03610-w · Cited by 42
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Attili, I., Passaro, A., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., & de Marinis, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102602 · Cited by 43
Corral, J., Majem, M., Rodríguez‐Abreu, D., Carcereny, E., Cortes, A. A., Llorente, M. D. M., López-Picazo, J. M., García, Y. G., Dómine, M., & Criado, M. P. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02053-7 · Cited by 42
Noordhof, A. L., Damhuis, R. A. M., Hendriks, L. E. L., Langen, A. J. D., Timens, W., Venmans, B. J. W., & van Geffen, W. H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.001 · Cited by 42
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna, L., Guibert, N. M., Milia, J., & Mazières, J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0652-3 · Cited by 43
Self-citationMan, J., Millican, J., Mulvey, A., Gebski, V., & Hui, R. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab012 · Cited by 40
Chen, J., Lu, W., Chen, M., Cai, Z., Zhan, P., Liu, X., Zhu, S., Ye, M., Lv, T., Lv, J., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225036 · Cited by 40
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
Friedlaender, A., Banna, G. L., Patel, S. H., & Addeo, A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0675-9 · Cited by 40
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Jimbu, L., Mesaros, O., Popescu, C., Neaga, A., Berceanu, I., Dima, D. M., Găman, M., & Zdrenghea, M. (2021) · Pharmaceuticals · doi:10.3390/ph14040288 · Cited by 41
Zhang, C., Chen, H., Shi, Y., Wu, L., Yan, L., Yan, X., Yue, D., Xu, C., Zheng, M., Li, J., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00301-8 · Cited by 39
Immunotherapy strategy of EGFR mutant lung cancer.
Yu, S., Liu, D., Shen, B., Shi, M., & Feng, J. (2018) · Europe PMC (PubMed Central) · Cited by 38
Jin, R., Zhao, J., Xia, L., Li, Q., Li, W., Peng, L., & Xia, Y. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920930333 · Cited by 39
Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769124 · Cited by 39
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 37
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Vokes, N. I., Pan, K., & Le, X. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231161409 · Cited by 40
Pretelli, G., Spagnolo, C. C., Ciappina, G., Santarpía, M., & Pasello, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108878 · Cited by 39
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36
Dai, J., Jiang, M., He, K., Wang, H., Chen, P., Guo, H., Zhao, W., Lu, H. J., He, Y., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708294 · Cited by 38
Yuchen, B., Xiaoxia, C., Hou, L., Qian, J., Jiang, T., Caicun, Z., & Ciebiada, M. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0223 · Cited by 36
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Yang, Y., Yu, Y., & Lü, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1622-5 · Cited by 37
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 44
Ryu, R. J., & Ward, K. E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00277 · Cited by 33
Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E. P. J. G., Aerts, J. G. J. V., & Voest, E. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4027 · Cited by 40
Liu, S., Wu, F., Li, X., Zhao, C., Jia, Y., Jia, K., Han, R., Qiao, M., Li, W., Yu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639947 · Cited by 36
Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Kim, S. Y., & Halmos, B. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0003 · Cited by 33
Self-citationOn-Target Side Effects of Targeted Therapeutics of Cancer
Tímár, J., & Uhlyarik, A. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610694 · Cited by 34
Liu, S., Tang, Q.-J., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L., et al. (2021) · Aging · doi:10.18632/aging.202811 · Cited by 33
Omori, S., Kenmotsu, H., Abe, M., Watanabe, R., Sugino, T., Kobayashi, H., Nakashima, K., Wakuda, K., Ono, A., Taira, T., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1305-4 · Cited by 32
Durvalumab for the treatment of non-small cell lung cancer
Mezquita, L., & Planchard, D. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1494575 · Cited by 34
Li, M., Gan, L., Song, A. J., Xue, J., & Lü, Y. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.004 · Cited by 33
Durvalumab for the treatment of non-small cell lung cancer
Murakami, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1699407 · Cited by 33
Self-citationClinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
Dagogo‐Jack, I., Azzolli, C. G., Fintelmann, F. J., Mino-Kenudson, M. A., Farago, A. F., Gainor, J. F., Jiang, G. Y., Piotrowska, Z., Heist, R. S., Lennes, I. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00299 · Cited by 33
Song, J. S., Kim, D., Kwon, J. H., Kim, H. R., Choi, C., & Jang, S. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01055 · Cited by 31
Self-citationClinical application of plasma mitochondrial DNA content in patients with lung cancer
Chen, J., Zhang, L., Yu, X., Zhou, H., Luo, Y., Wang, W., & Wang, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9515 · Cited by 32
Durvalumab in NSCLC: latest evidence and clinical potential
Muñoz-Unceta, N., Burgueño, I., Jiménez, E., & Paz-Ares, L. G. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918804151 · Cited by 30
Botticella, A., Mezquita, L., Pechoux, C. L., & Planchard, D. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619885530 · Cited by 30
Britschgi, C., Addeo, A., Rechsteiner, M., Delaloye, R., Früh, M., Metro, G., Banini, M., Gautschi, O. P., Rothschild, S. I., Wild, P. J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01299 · Cited by 31
Soares, M., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R. E. J., Chaib, C., Lacoin, L., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01270-z · Cited by 30
Kong, X., Lü, P., Liu, C., Guo, Y., Yang, Y., Peng, Y., Wang, F., Zhang, B., Dou, X., Shi, H., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12001 · Cited by 30
Pulmonary adverse events following immune checkpoint inhibitors
Spagnolo, P., Chaudhuri, N., Bernardinello, N., Karampitsakos, Τ., Sampsonas, F., & Tzouvelekis, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000895 · Cited by 31
Luciani, A., Marra, A., Toschi, L., Cortinovis, D. L., Fava, S., Filipazzi, V., Tuzi, A., Cerea, G., Rossi, S., Perfetti, V., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.004 · Cited by 29
Self-citationToxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02714-5 · Cited by 29
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
IFN-γ and CD38 in Hyperprogressive Cancer Development
Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 30
Gong, J., Gregg, J. P., Ma, W., Yoneda, K. Y., Moore, E. H., Daly, M. E., Zhang, Y., Williams, M. J., & Li, T. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7291 · Cited by 29
Garon, E. B., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A. V., Ahn, M., Robinet, G., Moulec, S. L., Natale, R. B., Schneider, J. G., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.02.010 · Cited by 28
Self-citationDou, S., Zhang, L., Wang, C., Yao, Y., Jiang, W. H., Ye, L., Li, J., Wu, S., Sun, D., Gong, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813732 · Cited by 28
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 31
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
Fujiwara, Y., Iguchi, H., Yamamoto, N., Hayama, M., Nii, M., Ueda, S., Komuro, K., Sugimoto, M., Vlahovic, G., & Kozuki, T. (2019) · Cancer Science · doi:10.1111/cas.14003 · Cited by 27
Liang, J., Li, M., Sui, Q., Hu, Z., Bian, Y., Huang, Y., Zhan, C., Jiang, W., Wang, Q., & Tan, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-192 · Cited by 27
Self-citationGavrilov, S. V., Zhudenkov, K., Helmlinger, G., Dunyak, J., Peskov, K. V., & Aksenov, S. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12578 · Cited by 27
Chen, Y., Chen, Z., Chen, R., Fang, C., Zhang, C., Ji, M. Q., & Yang, X. (2022) · Future Oncology · doi:10.2217/fon-2021-0862 · Cited by 30
Self-citationJohnson, M. L., Strauss, J. F., Patel, M. R., Garon, E. B., Eaton, K. D., Neskorik, T., Morin, J., Chao, R. C., & Halmos, B. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.013 · Cited by 27
Metadata
- Authors
- Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R. A., Huang, Y., Wadsworth, C., Dennis, P. A., Rizvi, N. A., Paz-Ares Rodriguez, L., Novello, S., Hiret, S., Schmid, P., Laack, E., Califano, R., Maemondo, M., Kim, S.-W., Chaft, J., Vicente Baz, D., Berghmans, T., Kim, D.-W., Surmont, V., Reck, M., Han, J.-Y., Holgado Martin, E., Belda Iniesta, C., Oe, Y., Chella, A., Chopra, A., Robinet, G., Soto Parra, H., Thomas, M., Cheema, P., Katakami, N., Su, W.-C., Kim, Y.-C., Wolf, J., Lee, J.-S., Saka, H., Milella, M., Ramos Garcia, I., Sibille, A., Yokoi, T., Kang, E. J., Atagi, S., Spaeth-Schwalbe, E., Nishio, M., Imamura, F., Gabrail, N., Veillon, R., Derijcke, S., Maeda, T., Zylla, D., Kubiak, K., Santoro, A., Uy, M. N., Lucien Geater, S., Italiano, A., Kowalski, D., Barlesi, F., Chen, Y.-M., Spigel, D., Chewaskulyong, B., Garcia Gomez, R., Alvarez Alvarez, R., Yang, C.-H., Hsia, T.-C., Denis, F., Sakai, H., Vincent, M., Goto, K., Bosch-Barrera, J., Weiss, G., Canon, J.-L., Scholz, C., Aglietta, M., Kemmotsu, H., Azuma, K., Bradbury, P., Feld, R., Chachoua, A., Jassem, J., Juergens, R., Palmero Sanchez, R., Malcolm, A., Vrindavanam, N., Kubota, K., Waller, C., Waterhouse, D., Coudert, B., Mark, Z., Satouchi, M., Chang, G.-C., Herzmann, C., Chaudhry, A., Giridharan, S., Hesketh, P., Ikeda, N., Boccia, R., Iannotti, N., Haigentz, M., Reynolds, J., Querol, J., Nakagawa, K., Sugawara, S., Tan, E. H., Hirashima, T., Gettinger, S., Kato, T., Takeda, K., Juan Vidal, O., Mohn-Staudner, A., Panwalkar, A., Daniel, D., Kobayashi, K., Ladrera, G. E. I., Schulte, C., Sebastian, M., Cernovska, M., Coupkova, H., Havel, L., Pauk, N., Singh, J., Murakami, S., Csoszi, T., Losonczy, G., Price, A., Anderson, I., Iqbal, M., Torri, V., Juhasz, E., Khanani, S., Koubkova, L., Levy, B., Page, R., Bocskei, C., Crinò, L., Einspahr, D., Hagenstad, C., Juat, N., Overton, L., Garrison, M., & Szalai, Z.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Yonsei University (KR)
- CHA University Bundang Medical Center (KR)
- Université Toulouse III - Paul Sabatier (FR)
- KU Leuven (BE)
- Moffitt Cancer Center (US)
- Carolina BioOncology Institute (US)
- Inserm (FR)
- Azienda Ospedaliera San Gerardo (IT)
- Samsung Medical Center (KR)
- National University Cancer Institute, Singapore (SG)
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Columbia University Irving Medical Center (US)
- University of Turin (IT)
- Institut de Cancérologie de l'Ouest (FR)
- Imperial College London (GB)
- Université Libre de Bruxelles (BE)
- German Center for Lung Research (DE)
- University of Palermo (IT)
- Hospital Universitario Virgen del Rocío (ES)
- University of Ottawa (CA)
- Corresponding author
- Garassino, Marina Chiara
- ORCID
- Garassino, Marina Chiara
- Cho, Byoung-Chul
- Kim, Joo-Hang
- Mazières, Julien
- Vansteenkiste, Johan
- Powderly, John
- Chouaid, Christos
- Park, Keunchil
- Soo, Ross A
- Huang, Yifan
- Rizvi, Naiyer A
- Novello, Silvia
- Hiret, Sandrine
- Schmid, Peter
- Califano, Raffaele
- Maemondo, Makoto
- Kim, Sang-We
- Chaft, Jamie
- Berghmans, Thierry
- Kim, Dong-Wan
- Surmont, Veerle
- Reck, Martin
- Han, Ji-Youn
- Chella, Antonio
- Chopra, Akhil
- Cheema, Parneet
- Katakami, Nobuyuki
- Su, Wu-Chou
- Kim, Young-Chul
- Lee, Jong-Seok
- Saka, Hideo
- Milella, Michele
- Sibille, Anne
- Yokoi, Takashi
- Kang, Eun Joo
- Atagi, Shinji
- Nishio, Makoto
- Imamura, Fumio
- Gabrail, Nashat
- Derijcke, Sofie
- Zylla, Dylan
- Santoro, Armando
- Kowalski, Dariusz
- Chen, Yuh-Min
- Spigel, David
- Hsia, Te-Chun
- Denis, Fabrice
- Sakai, Hiroshi
- Vincent, Mark
- Weiss, Glen
- Canon, Jean-Luc
- Aglietta, Massimo
- Azuma, Koichi
- Chachoua, Abraham
- Jassem, Jacek
- Juergens, Rosalyn
- Kubota, Kaoru
- Waller, Cornelius
- Waterhouse, David
- Coudert, Bruno
- Satouchi, Miyako
- Chang, Gee-Chen
- Herzmann, Christian
- Giridharan, Selvaraj
- Hesketh, Paul
- Ikeda, Norihiko
- Haigentz, Missak
- Nakagawa, Kazuhiko
- Sugawara, Shunichi
- Gettinger, Scott
- Kato, Terufumi
- Daniel, Davey
- Kobayashi, Kunihiko
- Sebastian, Martin
- Havel, Libor
- Singh, Joginder
- Murakami, Shuji
- Levy, Benjamin
- Page, Ray
- Crinò, Lucio
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 19
- Issue
- 4
- Pages
- 521-536
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7771363
- OpenAlex
- W2791290180
- Cited by
- 568
- References
- 29
- Citations by year
- 2026: 15 · 2025: 30 · 2024: 55 · 2023: 61 · 2022: 85 · 2021: 96 · 2020: 92 · 2019: 85 · 2018: 47
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- durvalumab, advanced non-small cell lung cancer, third-line therapy, PD-L1 expression, immune checkpoint inhibitors, EGFR mutation, ALK rearrangement, objective response rate, treatment safety, PD-L1 inhibitors, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Injection Site Reaction, Anaplastic Lymphoma Kinase, Progression-Free Survival, Aged, Antibodies, Monoclonal, Aspartate Aminotransferases, Carcinoma, Non-Small-Cell Lung, Diarrhea, Fatigue, Female, gamma-Glutamyltransferase, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pneumonia, 4-Butyrolactone, B7-H1 Antigen, Response Evaluation Criteria in Solid Tumors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
